Moreover, we also investigated the impact of prior therapy in relapsed/refractory patients, and intriguingly, patients treated with HMA-VEN displayed a higher frequency of CD25+ AML cells compared to treatment-naïve or chemo-treated patients (Supplementary Figure S5A). The gene discussed is IL2RA; the disease is acute myeloid leukemia.